Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial of Taxotere, Emcyt and Thalidomide (TET) for the Treatment of Hormone-Refractory Prostate Cancer

NCT00046826 is registered in ClinicalTrials.gov with Nuvance Health as lead sponsor.

NCT NCT00046826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00046826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial of Taxotere, Emcyt and Thalidomide (TET) for the Treatment of Hormone-Refractory Prostate Cancer
Lead sponsor
Nuvance Health
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2001
Completion date
October 31, 2009
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer